Akorn lays out $45M for Sunovion lung drug; Sanofi teams with Indian hospitals on diabetes clinics;

> Sunovion Pharmaceuticals said it would sell off rights to its respiratory drug Xoponex (levalbuterol) to Akorn ($AKRX) for $45 million. Release

> Sanofi ($SNY) teamed up with India's Apollo Hospitals on a diabetes-care program in India, delivered through a network of Apollo Sugar Clinics. Report

> Merck Serono tapped Hutchison China MediTech to market its beta blocker Ziac (bisoprolol HCl) in China. Report

> Pfizer Canada and WestJet launched a social media contest to raise awareness of anaphylaxis; Pfizer ($PFE) markets EpiPen in that country. Release

And Finally... Novo Nordisk ($NVO) and Diabetes UK started an awareness campaign, "Talk Hypos," to encourage diabetes patients to report hypoglycemia to their doctor or nurse. Release

Suggested Articles

The Pharma Lions shortlist for 2019 lives up to its name with just 31 entries making the cut. But it's still good news for the 12 drugmaker finalists.

Pharma companies filed suit Friday to block the new HHS rule that requires drugmakers to put list prices in TV ads.

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.